Proteomic analysis of the neuroprotective mechanisms of acupuncture treatment in a Parkinson's disease mouse model

Proteomics

Volumn 8, Issue 22, 2008, Pages 4822-4832

  Jeon, Songhee ^a   Youn, Jung Kim ^b   Kim, Seung Tae ^b   Moon, Woongjoon ^b   Chae, Younbyoung ^b   Kang, Minjeong ^b   Chung, Mi Young ^b   Lee, Hyangsook ^b   Hong, Mi Sook ^b   Chung, Joo Ho ^b   Joh, Tong H ^c   Lee, Hyejung ^b   Park, Hi Joon ^b  

^a Dongguk University   (South Korea)

^b Kyung Hee University   (South Korea)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Acupuncture; Cyclophilin A; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYCLOPHILIN A; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; ELECTROACUPUNCTURE; INFLAMMATION; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ACUPUNCTURE POINTS; ANALYSIS OF VARIANCE; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYCLOPHILIN A; DOPAMINE AGENTS; ELECTROACUPUNCTURE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION REGULATION; MICE; MODELS, ANIMAL; NEURONS; PARKINSON DISEASE; PEPTIDE MAPPING; PROTEOME; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; MUS;

EID: 55849130699     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200700955     Document Type: Article

References (53)

1. Rajendran, P. R., Thompson, R. E., Reich, S. G., The use of alternative therapies by patients with Parkinson's disease. Neurology 2001, 57, 790-794.
2. Park, H. J., Lim, S., Joo, W. S., Yin, C. S. et al., Acupuncture prevents 6-hydroxydopamine-induced neuronal death in the nigrostriatal dopaminergic system in the rat Parkinson's disease model. Exp. Neurol. 2003, 180, 93-98.
3. Ha, J. Y., Lee, S. H., Yin, C. S., Park, S. M. et al., The effect of manual acupuncture therapy on symptoms of the patients with idiopathic Parkinson's disease. J. Korean Orient. Med. 2003, 24, 172-183.
4. Kang, J. M., Park, H. J., Choi, Y. G., Choe, I. H. et al., Acupuncture inhibits microglial activation and inflammatory events in the MPTP-induced mouse model. Brain Res. 2007, 1131, 211-219.
5. Eng, M. L., Lyons, K. E., Greene, M. S., Pahwa, R., Open-label trial regarding the use of acupuncture and yin tui na in Parkinson's disease outpatients: A pilot study on efficacy, tolerability, and quality of life. J. Altern. Complement. Med. 2006, 12, 395-399.
6. Cristian, A., Katz, M., Cutrone, E., Walker, R. H., Evaluation of acupuncture in the treatment of Parkinson's disease: A double-blind pilot study. Mov. Disord. 2005, 20, 1185-1188.
7. Kim, Y. K., Lim, H. H., Song, Y. K., Lee, H. H. et al., Effect of acupuncture on 6-hydroxydopamine-induced nigrostratal dopaminergic neuronal cell death in rats. Neurosci. Lett. 2005, 384, 133-138.
8. Liang, X. B., Liu, X. Y., Li, F. Q., Luo, Y. et al., Long-term high-frequency electro-acupuncture stimulation prevents neuronal degeneration and up-regulates BDNF mRNA in the substantia nigra and ventral tegmental area following medial forebrain bundle axotomy. Brain Res. Mol. Brain Res. 2002, 108, 51-59.
9. Liang, X. B., Luo, Y., Liu, X. Y., Lu, J. et al., Electro-acupuncture improves behavior and upregulates GDNF mRNA in MFB transected rats. Neuroreport 2003, 14, 1177-1181.
10. Dehmer, T., Lindenau, J., Haid, S., Dichgans, J., Schulz, J. B., Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 2000, 74, 2213-2216.
11. Hayley, S., Crocker, S. J., Smith, P. D., Shree, T. et al., Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine model of Parkinson's disease. J. Neurosci. 2004, 24, 2045-2053.
12. Yin, C. S., Jeong, H. S., Park, H. J., Baik, Y. et al., A proposed transpositional acupoint system in a mouse and rat model. Res. Vet. Sci. 2008, 84, 159-165.
13. MacPherson, H., White, A., Cummings, M., Jobst, K. A. et al., Standards for reporting interventions in controlled trials of acupuncture: The STRICTA recommendations. J. Altern. Complement. Med. 2002, 8, 85-89.
14. Manheimer, E., Linde, K., Lao, L., Bouter, L. M., Berman, B. M., Meta-analysis: Acupuncture for osteoarthritis of the knee. Ann. Intern. Med. 2007, 146, 868-877.
15. Abe, K., Taguchi, K., Wasai, T., Ren, J. et al., Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse. Brain Res. 2001, 907, 134-138.
16. Hirsch, E. C., Faucheux, B. A., Iron metabolism and Parkinson's disease. Mov. Disord. 1998, 13, 39-45.
17. Hirsch, E. C., Hunot, S., Damier, P., Faucheux, B., Glial cells and inflammation in Parkinson's disease: A role in neurodegeneration? Ann. Neurol. 1998, 44, S115-S120.
18. Noureddine, M. A., Li, Y. J., van der Walt, J. M., Walters, R. et al., Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra. Mov. Disord. 2005, 20, 1299-1309.
19. Kim, J. M., Lee, K. H., Jeon, Y. J., Oh, J. H. et al., Identification of genes related to Parkinson's disease using expressed sequence tags. DNA Res. 2006, 13, 275-286.
20. Ciechanover, A., Brundin, P., The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg. Neuron 2003, 40, 427-446.
21. Dawson, T. M., Dawson, V. L., Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302, 819-822.
22. Orlowski, M., The multicatalytic proteinase complex (proteasome) and intracellular protein degradation: Diverse functions of an intracellular particle. J. Lab. Clin. Med. 1993, 121, 187-189.
23. Coux, O., Tanaka, K., Goldberg, A. L., Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 1996, 65, 801-847.
24. Mount, M. P., Lira, A., Grimes, D., Smith, P. D. et al., Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J. Neurosci. 2007, 27, 3328-3337.
25. Habelhah, H., Takahashi, S., Cho, S. G., Kadoya, T. et al., Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB. EMBO J. 2004, 23, 322-332.
26. Chen, K. Y., Liu, A. Y., Biochemistry and function of hypusine formation on eukaryotic initiation factor 5A. Biol. Signals 1997, 6, 105-109.
27. Chen, L., Xu, Q., Liu, X. L., Zhao, J., Ma, L., Differential and Tissue-specific Expression of Mitochondrial Elongation Factor Tu and Ts during Development. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao 1999, 31, 37-40.
28. Park, M. H., Lee, Y. B., Joe, Y. A., Hypusine is essential for eukaryotic cell proliferation. Biol. Signals 1997, 6, 115-123.
29. Caraglia, M., Tagliaferri, P., Budillon, A., Abbruzzese, A., Post-translational modifications of eukaryotic initiation factor-5A (eIF-5A) as a new target for anti-cancer therapy. Adv. Exp. Med. Biol. 1999, 472, 187-198.
30. Jin, B. F., He, K., Wang, H. X., Wang, J. et al., Proteomic analysis of ubiquitin-proteasome effects: insight into the function of eukaryotic initiation factor 5A. Oncogene 2003, 22, 4819-4830.
31. de Hostos, E. L., Bradtke, B., Lottspeich, F., Gerisch, G., Coactosin, a 17 kDa F-actin binding protein from Dictyostelium discoideum. Cell Motil. Cytoskeleton 1993, 26, 181-191.
32. Provost, P., Samuelsson, B., Radmark, O., Interaction of 5-lipoxygenase with cellular proteins. Proc. Natl. Acad. Sci. USA 1999, 96, 1881-1885.
33. Doucet, J., Provost, P., Samuelsson, B., Radmark, O., Molecular cloning and functional characterization of mouse coactosin-like protein. Biochem. Biophys. Res. Commun. 2002, 290, 783-789.
34. Provost, P., Doucet, J., Stock, A., Gerisch, G. et al., Coactosin-like protein, a human F-actin-binding protein: Critical role of lysine-75. Biochem. J. 2001, 359, 255-263.
35. Rakonjac, M., Fischer, L., Provost, P., Werz, O. et al., Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A4 production. Proc. Natl. Acad. Sci. USA 2006, 103, 13150-13155.
36. Floto, R. A., Smith, K. G., The vagus nerve, macrophages, and nicotine. Lancet 2003, 361, 1069-1070.
37. Wilson, D. W., Wilcox, C. A., Flynn, G. C., Chen, E. et al., A fusion protein required for vesicle-mediated transport in both mammalian cells and yeast. Nature 1989, 339, 355-359.
38. Sollner, T., Bennett, M. K., Whiteheart, S. W., Scheller, R. H., Rothman, J. E., A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion. Cell 1993, 75, 409-418.
39. Schiavo, G., Gmachl, M. J., Stenbeck, G., Sollner, T. H., Rothman, J. E., A possible docking and fusion particle for synaptic transmission. Nature 1995, 378, 733-736.
40. Colgan, J., Asmal, M., Neagu, M., Yu, B. et al., Cyclophilin A regulates TCR signal strength in CD41 T cells via a proline-directed conformational switch in Itk. Immunity 2004, 21, 189-201.
41. Göldner, F. M., Patrick, J. W., Neuronal localization of the cyclophilin A protein in the adult rat brain. J. Comp. Neurol. 1996, 372, 283-293.
42. Nahreini, P., Hovland, A. R., Kumar, B., Andreatta, C. et al., Effects of altered cyclophilin A expression on growth and differentiation of human and mouse neuronal cells. Cell. Mol. Neurobiol. 2001, 21, 65-79.
43. Avramut, M., Achim, C. L., Immunophilins in nervous system degeneration and regeneration. Curr. Top. Med. Chem. 2003, 3, 1376-1382.
44. Doyle, V., Virji, S., Crompton, M., Evidence that cyclophilin-A protects cells against oxidative stress. Biochem. J. 1999, 341, 127-132.
45. Boulos, S., Meloni, B. P., Arthur, P. G., Majda, B. et al., Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptor-mediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury. Neurobiol. Dis. 2007, 25, 54-64.
46. Piotukh, K., Gu, W., Kofler, M., Labudde, D. et al., Cyclophilin A binds to linear peptide motifs containing a consensus that is present in many human proteins. J. Biol. Chem. 2005, 280, 23668-23674.
47. Yurchenko, V., Zybarth, G., O'Connor, M., Dai, W. W. et al., Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J. Biol. Chem. 2002, 277, 22959-22965.
48. Redell, J. B., Zhao, J., Dash, P. K., Acutely increased cyclophilin A expression after brain injury: A role in blood-brain barrier function and tissue preservation. J. Neurosci. Res. 2007, 85, 1980-1988.
49. Mattson, M. P., Cheng, B., Smith-Swintosky, V. L., Mechanisms of neurotrophic factor protection against calcium- and free radical-mediated excitotoxic injury: Implications for treating neurodegenerative disorders. Exp. Neurol. 1993, 124, 89-95.
50. Mattson, M. P., Duan, W., Wan, R., Guo, Z., Prophylactic activation of neuroprotective stress response pathways by dietary and behavioral manipulations. NeuroRx 2004, 1, 111-116.
51. Duan, W., Mattson, M. P., Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. Res. 1999, 57, 195-206.
52. Han, J. S., Acupuncture and endorphins. Neurosci. Lett. 2004, 361, 258-261.
53. Zhang, W. T., Jin, Z., Luo, F., Zhang, L. et al., Evidence from brain imaging with fMRI supporting functional specificity of acupoints in humans. Neurosci. Lett. 2004, 354, 50-53.